New Alzheimer’s Drug Slows Cognitive Decline

Alzheimer's is the most common form of Dementia, a broad term for cognitive decline and memory loss beyond normal ageing. Currently, 55 million people are living with dementia, and it's the 7th leading cause of death in the world. This new drug, Lecanemab, reduced the cognitive decline of Alzheimer’s patients by 27% and could help early-stage sufferers stay healthy for longer in a Phase III trial. Here’s more about it.